Uchini S. Kosgodage 1 , Paul Matewele 1 , Brigitte Awamaria 1 , Igor Kraev 2 , Purva Warde 3 , Giulia Mastroianni 4 , Alistair V. Nunn 5 , Geoffrey W. Guy 6 , Jimmy D. Bell 5 , Jameel M. Inal 3 , Sigrun Lange 7 , *
10 September 2019
Membrane vesicles (MVs) released from bacteria participate in cell communication and host-pathogen interactions. Roles for MVs in antibiotic resistance are gaining increased attention and in this study we investigated if known anti-bacterial effects of cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, could be in part attributed to effects on bacterial MV profile and MV release. We found that CBD is a strong inhibitor of MV release from Gram-negative bacteria ( E. coli VCS257), while inhibitory effect on MV release from Gram-positive bacteria ( S. aureus subsp . aureus Rosenbach) was negligible. When used in combination with selected antibiotics, CBD significantly increased the bactericidal action of several antibiotics in the Gram-negative bacteria. In addition, CBD increased antibiotic effects of kanamycin in the Gram-positive bacteria, without affecting MV release. CBD furthermore changed protein profiles of MVs released from E. coli after 1 h CBD treatment. Our findings indicate that CBD may pose as a putative adjuvant agent for tailored co-application with selected antibiotics, depending on bacterial species, to increase antibiotic activity, including via MV inhibition, and help reduce antibiotic resistance.